Oral PDE-4 Inhibitor, OTEZLA®, Approved for the Treatment of Plaque Psoriasis and Psoriatic Arthritis in Japan
SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) today announced that OTEZLA ® (apremilast), Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4), has been granted full marketing...